European Commission approves ACAD's DAYBU for Rett syndrome
ACAD says the European Commission approves DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.